Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Akcea Therapeutics appoints William Andrews as chief medical officer » 07:05
07/09/20
07/09
07:05
07/09/20
07:05
AKCA

Akcea Therapeutics

$13.88 /

-0.18 (-1.28%)

, IONS

Ionis Pharmaceuticals

$60.90 /

-0.39 (-0.64%)

, ACER

Acer Therapeutics

$3.21 /

+0.07 (+2.23%)

Akcea Therapeutics…

Akcea Therapeutics (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals (IONS), announced that William Andrews, MD, FACP, has joined the company as chief medical officer, effective immediately. Dr. Andrews will lead medical, clinical and regulatory functions in support of the company's two commercial-stage products TEGSEDI and WAYLIVRA and will also guide development of the multiple clinical-stage therapeutics in the pipeline. Former CMO Louis St. L. O'Dea, MB, BCh, BAO, FRCP, will serve as an advisor to the company to ensure a smooth transition. Most recently DR. Andrews served as chief medical officer at Acer Therapeutics (ACER).

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$60.90 /

-0.39 (-0.64%)

AKCA Akcea Therapeutics
$13.88 /

-0.18 (-1.28%)

ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

AKCA Akcea Therapeutics
$13.88 /

-0.18 (-1.28%)

01/22/20 Stifel
Akcea LICA data look 'solid,' as expected, says Stifel
10/08/19 BMO Capital
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
10/07/19 Stifel
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
10/07/19
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
IONS Ionis Pharmaceuticals
$60.90 /

-0.39 (-0.64%)

06/05/20 Citi
Ionis Pharmaceuticals price target raised to $80 from $71 at Citi
05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

IONS Ionis Pharmaceuticals
$60.90 /

-0.39 (-0.64%)

AKCA Akcea Therapeutics
$13.88 /

-0.18 (-1.28%)

ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

IONS Ionis Pharmaceuticals
$60.90 /

-0.39 (-0.64%)

Wednesday
On The Fly
Fly Intel: After-Hours Movers » 18:59
07/08/20
07/08
18:59
07/08/20
18:59
EXFO

EXFO Inc.

$3.24 /

+0.1 (+3.18%)

, SAR

Saratoga Investment

$15.61 /

+0.475 (+3.14%)

, ACER

Acer Therapeutics

$3.21 /

+0.07 (+2.23%)

, OPTN

Optinose

$4.26 /

-0.28 (-6.17%)

, ANAB

AnaptysBio

$22.71 /

+0.05 (+0.22%)

, VERI

Veritone

$12.11 /

-0.26 (-2.10%)

, PTC

PTC

$78.36 /

+1.76 (+2.30%)

, SAP

SAP

$146.75 /

+2.75 (+1.91%)

, CRNX

Crinetics

$16.46 /

-0.62 (-3.63%)

, FTCH

Farfetch

$19.59 /

+1.4 (+7.70%)

, COST

Costco

$316.38 /

+0.095 (+0.03%)

, REGN

Regeneron

$639.69 /

-0.92 (-0.14%)

, BBBY

Bed Bath & Beyond

$10.40 /

+0.15 (+1.46%)

, OTIC

Otonomy

$3.58 /

+0.01 (+0.28%)

, GLG

TD Holdings

$2.44 /

+0.06 (+2.52%)

, TPB

Turning Point Brands

$26.50 /

+1.945 (+7.92%)

, FIVE

Five Below

$103.28 /

+4.72 (+4.79%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VERI Veritone
$12.11 /

-0.26 (-2.10%)

TPB Turning Point Brands
$26.50 /

+1.945 (+7.92%)

SAR Saratoga Investment
$15.61 /

+0.475 (+3.14%)

SAP SAP
$146.75 /

+2.75 (+1.91%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

PTC PTC
$78.36 /

+1.76 (+2.30%)

OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

OPTN Optinose
$4.26 /

-0.28 (-6.17%)

GLG TD Holdings
$2.44 /

+0.06 (+2.52%)

FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

FIVE Five Below
$103.28 /

+4.72 (+4.79%)

EXFO EXFO Inc.
$3.24 /

+0.1 (+3.18%)

CRNX Crinetics
$16.46 /

-0.62 (-3.63%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

ANAB AnaptysBio
$22.71 /

+0.05 (+0.22%)

ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

EXFO EXFO Inc.
$3.24 /

+0.1 (+3.18%)

SAR Saratoga Investment
$15.61 /

+0.475 (+3.14%)

01/13/20 Ladenburg
Saratoga Investment upgraded to Buy from Neutral at Ladenburg
01/09/20 Compass Point
Saratoga Investment upgraded to Buy from Neutral at Compass Point
12/19/19 National Securities
Saratoga Investment initiated with a Neutral at National Securities
08/29/19 Aegis
Saratoga Investment initiated with a Buy at Aegis
ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

OPTN Optinose
$4.26 /

-0.28 (-6.17%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
02/07/20 Piper Sandler
Piper Sandler views Optinose risk/reward as attractive after allergist survery
12/18/19 Cowen
Optinose initiated with an Outperform at Cowen
10/01/19 Jefferies
Optinose risk/reward looks increasingly attractive, says Jefferies
ANAB AnaptysBio
$22.71 /

+0.05 (+0.22%)

01/16/20 Cantor Fitzgerald
AnaptysBio risk/reward favorable into second half data, says Cantor Fitzgerald
11/11/19 SunTrust
AnaptysBio downgraded to Hold from Buy at SunTrust
11/08/19 Cantor Fitzgerald
Cantor cuts AnaptysBio target to $28 from $140, sees value in shares
11/08/19 Jefferies
AnaptysBio downgraded to Hold from Buy at Jefferies
VERI Veritone
$12.11 /

-0.26 (-2.10%)

07/06/20 Craig-Hallum
Craig-Hallum says sell Veritone after stock surpasses 'reasonable' valuation
07/06/20 Craig-Hallum
Veritone downgraded to Sell from Hold at Craig-Hallum
06/25/20 Roth Capital
Veritone price target raised to $18 from $7 at Roth Capital
11/08/19 JMP Securities
Veritone price target lowered to $7 from $10 at JMP Securities
PTC PTC
$78.36 /

+1.76 (+2.30%)

06/11/20 Rosenblatt
PTC's highly recurring revenue model underappreciated, says Rosenblatt
06/11/20 Wedbush
PTC price target raised to $78 from $70 at Wedbush
06/10/20 Mizuho
PTC price target raised to $95 from $80 at Mizuho
06/05/20 Needham
PTC initiated with a Buy at Needham
SAP SAP
$146.75 /

+2.75 (+1.91%)

07/08/20 UBS
SAP price target raised to EUR 142 from EUR 118 at UBS
06/16/20 Oppenheimer
SAP price target raised to $137 from $115 at Oppenheimer
06/16/20 RBC Capital
SAP price target raised to $142 from $117 at RBC Capital
06/15/20 Jefferies
SAP price target raised to $149 from $145 at Jefferies
CRNX Crinetics
$16.46 /

-0.62 (-3.63%)

05/11/20 Cantor Fitzgerald
Crinetics price target raised to $38 from $28 at Cantor Fitzgerald
05/08/20 Piper Sandler
Piper Sandler continues to recommend Crinetics after paltusotine data
04/07/20 Piper Sandler
Crinetics shares 'should be up meaningfully,' says Piper Sandler
12/23/19 Roth Capital
Crinetics initiated with a Buy at Roth Capital
FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

07/08/20 China Renaissance
Farfetch upgraded to Buy from Hold at China Renaissance
07/01/20 Deutsche Bank
Farfetch price target raised to $23 from $17 at Deutsche Bank
06/26/20 KeyBanc
Farfetch price target raised to $23 from $17 at KeyBanc
06/25/20 BTIG
Farfetch upgraded to Buy from Neutral at BTIG
COST Costco
$316.38 /

+0.095 (+0.03%)

05/29/20 Baird
Costco improved comps seen likely for May, says Baird
05/29/20 RBC Capital
Costco price target raised to $348 from $332 at RBC Capital
05/06/20 Baird
Costco SSS decline due to pressure from temporal factors, says Baird
04/15/20 Citi
Costco assumed with a Neutral at Citi
REGN Regeneron
$639.69 /

-0.92 (-0.14%)

07/08/20 SunTrust
Regeneron upgraded to Buy at SunTrust on Eylea resilience and pipeline
07/08/20 SunTrust
Regeneron upgraded to Buy from Hold at SunTrust
07/08/20 Canaccord
Regeneron price target raised to $700 from $660 at Canaccord
07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

07/07/20 Raymond James
Bed Bath & Beyond price target raised to $13 from $9 at Raymond James
05/26/20 Odeon Capital
Bed Bath & Beyond upgraded to Buy from Hold at Odeon Capital
04/16/20 Loop Capital
Bed Bath & Beyond Q4 results 'less bad than feared' says Loop Capital
04/08/20 Loop Capital
Bed Bath & Beyond price target lowered to $5 from $12 at Loop Capital
OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

07/07/20 Cantor Fitzgerald
Otonomy price target raised to $11 from $9 at Cantor Fitzgerald
07/07/20 H.C. Wainwright
Otonomy price target raised to $9 from $8 at H.C. Wainwright
06/15/20 Piper Sandler
Piper remains optimistic on Otonomy ahead of near-term clinical readouts
06/01/20 Oppenheimer
Otonomy assumed with an Outperform at Oppenheimer
GLG TD Holdings
$2.44 /

+0.06 (+2.52%)

TPB Turning Point Brands
$26.50 /

+1.945 (+7.92%)

07/08/20 Craig-Hallum
Turning Point Brands initiated with a Buy at Craig-Hallum
01/06/20 Buckingham
Vape plan looks better than expected for Turning Point, says Buckingham
11/26/19 Buckingham
Buckingham starts Turning Point at Buy, says 'far more than a vaping play'
11/26/19 Buckingham
Turning Point Brands initiated with a Buy at Buckingham
FIVE Five Below
$103.28 /

+4.72 (+4.79%)

06/10/20
Fly Intel: Top five analyst upgrades
06/10/20 JPMorgan
Five Below price target raised to $123 from $103 at JPMorgan
06/10/20 Jefferies
Five Below price target raised to $140 from $89 at Jefferies
06/10/20 Credit Suisse
Five Below price target raised to $116 from $93 at Credit Suisse
VERI Veritone
$12.11 /

-0.26 (-2.10%)

TPB Turning Point Brands
$26.50 /

+1.945 (+7.92%)

SAR Saratoga Investment
$15.61 /

+0.475 (+3.14%)

SAP SAP
$146.75 /

+2.75 (+1.91%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

PTC PTC
$78.36 /

+1.76 (+2.30%)

OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

OPTN Optinose
$4.26 /

-0.28 (-6.17%)

FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

FIVE Five Below
$103.28 /

+4.72 (+4.79%)

EXFO EXFO Inc.
$3.24 /

+0.1 (+3.18%)

CRNX Crinetics
$16.46 /

-0.62 (-3.63%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

ANAB AnaptysBio
$22.71 /

+0.05 (+0.22%)

ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

  • 09
    Jul
  • 09
    Jul
  • 27
    May
  • 15
    Apr
  • 21
    Nov
SAP SAP
$146.75 /

+2.75 (+1.91%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

SAR Saratoga Investment
$15.61 /

+0.475 (+3.14%)

SAP SAP
$146.75 /

+2.75 (+1.91%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

FIVE Five Below
$103.28 /

+4.72 (+4.79%)

EXFO EXFO Inc.
$3.24 /

+0.1 (+3.18%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

FIVE Five Below
$103.28 /

+4.72 (+4.79%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

Hot Stocks
Acer Therapeutics announces data from food effect study of ACER-001 » 16:07
07/08/20
07/08
16:07
07/08/20
16:07
ACER

Acer Therapeutics

$3.16 /

+0.02 (+0.64%)

Acer Therapeutics…

Acer Therapeutics announced data from a food effect study in healthy volunteers showing that administration of ACER-001 in a fasted state increased systemic exposure of phenylbutyrate, or PBA, phenylacetate, or PAA and phenylacetylglutamine, or PAGN, levels compared to fed state, and therefore based on modeling data may improve disease management in patients with urea cycle disorders, or UCDs, when compared to currently approved treatments requiring administration with food. Results from Part B of the ACER-001 bioequivalence, or BE, trial in healthy volunteers announced in February showed that ACER-001 was bioequivalent to Buphenyl and were within the parameters recommended by the FDA's Guidance for Industry. The BE trial included a food effect study, which evaluated the pharmacokinetics, or PK, of sodium phenylbutyrate showing that administration of ACER-001 in a fasted state achieved more than two times the maximum concentration of PBA compared to administration of the same dose of ACER-001 in a fed state. These results are consistent with previously published that evaluated PK of NaPBA in patients with progressive familial intrahepatic cholestasis, also demonstrating that administration of NaPBA in a fasted state significantly increased PBA peak plasma concentration compared to administration of NaPBA in a fed state. Based on the results from the food effect study within the ACER-001 BE trial, Acer commissioned Rosa & Co. to create a PhysioPD PK model to evaluate the potential food effect on exposure, tolerability and efficacy of ACER-001 in UCDs patients. Results from this in silico model suggest that administration of ACER-001 in a fasted state required approximately 30% less PBA to achieve comparable therapeutic benefit in a fed state. In addition, the model predicted that administration of ACER-001 in a fasted state compared to administration of Buphenyl or Ravicti in their required fed states is expected to result in higher peak blood PBA, PAA and PAGN concentrations, predicting a 43% increase in urinary PAGN levels.

ShowHide Related Items >><<
ACER Acer Therapeutics
$3.16 /

+0.02 (+0.64%)

ACER Acer Therapeutics
$3.16 /

+0.02 (+0.64%)

ACER Acer Therapeutics
$3.16 /

+0.02 (+0.64%)

Over a month ago
Hot Stocks
Acer jumps after Nature article on COVID therapy targets » 16:25
05/19/20
05/19
16:25
05/19/20
16:25
ACER

Acer Therapeutics

$4.52 /

+1 (+28.41%)

A late day surge in…

A late day surge in shares of Acer Therapeutics, that is carrying over to after-hours trading, is being attributed to the circulation of a Nature article regarding "Proteomics of SARS-CoV-2-infected host cells reveals therapy targets." The accelerated article preview, which was published online on May 14, stated that the clinical researchers "speculated that SARS-CoV-2 replication might be sensitive to translation inhibition. We tested two translation inhibitors - cycloheximide and emetine - for their ability to reduce SARS-CoV-2 replication. Both compounds significantly inhibited SARS-CoV-2 replication at non-toxic concentrations. Taken together, translatome analyses of cells infected with SARS-CoV-2 revealed the temporal profile of viral and host protein responses with prominent increases in the translation machinery. Translation inhibitors prevented SARS-CoV-2 replication in cells." On May 11, Acer Therapeutics announced it has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences, or NCATS, one of the National Institutes of Health, or NIH, to develop emetine hydrochloride as a potential treatment for patients with COVID-19, the disease caused by infection with the SARS-CoV-2 virus. In after-hours trading, shares of Acer Therapeutics are up 83c, or 18%, to $5.36. Reference Link

ShowHide Related Items >><<
ACER Acer Therapeutics
$4.52 /

+1 (+28.41%)

ACER Acer Therapeutics
$4.52 /

+1 (+28.41%)

06/26/19 H.C. Wainwright
Acer Therapeutics price target lowered to $10 from $55 at H.C. Wainwright
06/25/19 Roth Capital
Acer Therapeutics price target lowered to $9 from $66 at Roth Capital
06/25/19 Raymond James
Raymond James doesn't see path forward for Edsivo, cuts Acer to Market Perform
06/25/19 Raymond James
Acer Therapeutics downgraded to Market Perform from Outperform at Raymond James
ACER Acer Therapeutics
$4.52 /

+1 (+28.41%)

ACER Acer Therapeutics
$4.52 /

+1 (+28.41%)

Earnings
Acer says cash position sufficient to fund operations into Q4 of 2020 » 16:06
05/14/20
05/14
16:06
05/14/20
16:06
ACER

Acer Therapeutics

$3.55 /

-0.03 (-0.84%)

Acer believes its cash…

Acer believes its cash position will be sufficient to fund its current operations into Q4 f 2020, excluding support for a planned emetine clinical trial and for EDSIVO development and precommercial activities.

ShowHide Related Items >><<
ACER Acer Therapeutics
$3.55 /

-0.03 (-0.84%)

ACER Acer Therapeutics
$3.55 /

-0.03 (-0.84%)

06/26/19 H.C. Wainwright
Acer Therapeutics price target lowered to $10 from $55 at H.C. Wainwright
06/25/19 Roth Capital
Acer Therapeutics price target lowered to $9 from $66 at Roth Capital
06/25/19 Raymond James
Raymond James doesn't see path forward for Edsivo, cuts Acer to Market Perform
06/25/19 Raymond James
Acer Therapeutics downgraded to Market Perform from Outperform at Raymond James
ACER Acer Therapeutics
$3.55 /

-0.03 (-0.84%)

ACER Acer Therapeutics
$3.55 /

-0.03 (-0.84%)

Earnings
Acer Therapeutics reports Q1 EPS (49c), consensus (40c) » 16:05
05/14/20
05/14
16:05
05/14/20
16:05
ACER

Acer Therapeutics

$3.55 /

-0.03 (-0.84%)

Cash and cash equivalents…

Cash and cash equivalents were $7.0M as of March 31, compared to $12.1M as of December 31, 2019.

ShowHide Related Items >><<
ACER Acer Therapeutics
$3.55 /

-0.03 (-0.84%)

ACER Acer Therapeutics
$3.55 /

-0.03 (-0.84%)

06/26/19 H.C. Wainwright
Acer Therapeutics price target lowered to $10 from $55 at H.C. Wainwright
06/25/19 Roth Capital
Acer Therapeutics price target lowered to $9 from $66 at Roth Capital
06/25/19 Raymond James
Raymond James doesn't see path forward for Edsivo, cuts Acer to Market Perform
06/25/19 Raymond James
Acer Therapeutics downgraded to Market Perform from Outperform at Raymond James
ACER Acer Therapeutics
$3.55 /

-0.03 (-0.84%)

ACER Acer Therapeutics
$3.55 /

-0.03 (-0.84%)

On The Fly
Fly Intel: After-Hours Movers » 19:14
05/12/20
05/12
19:14
05/12/20
19:14
UBER

Uber

$32.38 /

+0.73 (+2.31%)

, GRUB

GrubHub

$60.39 /

+13.57 (+28.98%)

, PODD

Insulet

$220.81 /

-3.98 (-1.77%)

, ACER

Acer Therapeutics

$3.75 /

+0.59 (+18.67%)

, PRPL

Purple Innovation

$13.65 /

+0.62 (+4.76%)

, TCS

Container Store

$2.58 /

+0.295 (+12.94%)

, ATOM

Atomera

$6.60 /

+1.09 (+19.78%)

, CRHM

CRH Medical

$1.89 /

-0.07 (-3.57%)

, ADPT

Adaptive Biotechnologies

$38.10 /

-0.03 (-0.08%)

, EGHT

8x8, Inc.

$20.51 /

+0.63 (+3.17%)

, SWAV

ShockWave Medical

$41.08 /

-0.7 (-1.68%)

, INFN

Infinera

$5.81 /

+0.17 (+3.01%)

, PBPB

Potbelly

$2.98 /

-0.03 (-1.00%)

, VREX

Varex Imaging

$25.33 /

-0.86 (-3.28%)

, WW

WW

$23.48 /

-0.6 (-2.49%)

, UNFI

United Natural Foods

$15.54 /

+2.87 (+22.65%)

, ALGT

Allegiant Travel

$73.36 /

-0.56 (-0.76%)

, OSMT

Osmotica Pharmaceuticals

$4.67 /

+0.3 (+6.86%)

, XP

XP Inc.

$25.10 /

-0.19 (-0.75%)

, PGNY

Progyny

$20.29 /

-1.22 (-5.67%)

, AVNW

Aviat Networks

$9.45 /

-0.35 (-3.57%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
XP XP Inc.
$25.10 /

-0.19 (-0.75%)

WW WW
$23.48 /

-0.6 (-2.49%)

VREX Varex Imaging
$25.33 /

-0.86 (-3.28%)

UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

UBER Uber
$32.38 /

+0.73 (+2.31%)

TCS Container Store
$2.58 /

+0.295 (+12.94%)

SWAV ShockWave Medical
$41.08 /

-0.7 (-1.68%)

PRPL Purple Innovation
$13.65 /

+0.62 (+4.76%)

PODD Insulet
$220.81 /

-3.98 (-1.77%)

PGNY Progyny
$20.29 /

-1.22 (-5.67%)

PBPB Potbelly
$2.98 /

-0.03 (-1.00%)

OSMT Osmotica Pharmaceuticals
$4.67 /

+0.3 (+6.86%)

INFN Infinera
$5.81 /

+0.17 (+3.01%)

GRUB GrubHub
$60.39 /

+13.57 (+28.98%)

EGHT 8x8, Inc.
$20.51 /

+0.63 (+3.17%)

CRHM CRH Medical
$1.89 /

-0.07 (-3.57%)

AVNW Aviat Networks
$9.45 /

-0.35 (-3.57%)

ATOM Atomera
$6.60 /

+1.09 (+19.78%)

ALGT Allegiant Travel
$73.36 /

-0.56 (-0.76%)

ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

ACER Acer Therapeutics
$3.75 /

+0.59 (+18.67%)

UBER Uber
$32.38 /

+0.73 (+2.31%)

05/12/20 DA Davidson
DA Davidson keeps Underperform rating on GrubHub following reports of Uber talks
05/12/20 KeyBanc
KeyBanc upgrades GrubHub to Sector Weight on strategic sense of possible deal
05/12/20 Wedbush
Uber could face bidding war for GrubHub with Doordash, says Wedbush
05/12/20 Needham
Uber deal for GrubHub could accelerate food delivery profitability, says Needham
GRUB GrubHub
$60.39 /

+13.57 (+28.98%)

05/12/20 KeyBanc
GrubHub upgraded to Sector Weight from Underweight at KeyBanc
PODD Insulet
$220.81 /

-3.98 (-1.77%)

05/08/20 Baird
Insulet price target raised to $242 from $189 at Baird
05/08/20 SVB Leerink
Insulet price target raised to $230 from $200 at SVB Leerink
05/08/20 Citi
Insulet price target raised to $250 from $206 at Citi
04/24/20 SVB Leerink
Insulet downgraded to Market Perform from Outperform at SVB Leerink
ACER Acer Therapeutics
$3.75 /

+0.59 (+18.67%)

06/26/19 H.C. Wainwright
Acer Therapeutics price target lowered to $10 from $55 at H.C. Wainwright
06/25/19 Roth Capital
Acer Therapeutics price target lowered to $9 from $66 at Roth Capital
06/25/19 Raymond James
Raymond James doesn't see path forward for Edsivo, cuts Acer to Market Perform
06/25/19 Raymond James
Acer Therapeutics downgraded to Market Perform from Outperform at Raymond James
PRPL Purple Innovation
$13.65 /

+0.62 (+4.76%)

05/12/20 Wedbush
Purple Innovation price target raised to $17 from $11 at Wedbush
04/15/20 Oppenheimer
Conn's downgraded to Perform at Oppenheimer amid COVID-19 pandemic
03/25/20 Raymond James
Purple Innovation price target lowered to $10 from $13 at Raymond James
02/26/20 Wedbush
Casper Sleep initiated with a Neutral at Wedbush on 'aspirational' targets
TCS Container Store
$2.58 /

+0.295 (+12.94%)

10/17/19
Fly Intel: Top five analyst upgrades
10/17/19 Goldman Sachs
Container Store upgraded to Neutral from Sell at Goldman Sachs
07/11/19 Goldman Sachs
Container Store initiated with a Sell at Goldman Sachs
ATOM Atomera
$6.60 /

+1.09 (+19.78%)

CRHM CRH Medical
$1.89 /

-0.07 (-3.57%)

03/13/20 RBC Capital
CRH Medical price target lowered to C$4.75 from C$6.50 at RBC Capital
ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
11/13/19 JPMorgan
Adaptive Biotechnologies still has upside potential despite rally, says JPMorgan
07/23/19
Fly Intel: Top five analyst initiations
EGHT 8x8, Inc.
$20.51 /

+0.63 (+3.17%)

04/16/20 BTIG
8x8, Inc. initiated with a Buy at BTIG
04/14/20
Fly Intel: Top five analyst initiations
04/13/20 BTIG
8x8, Inc. initiated with a Buy at BTIG
03/26/20 B. Riley FBR
8x8, Inc. downgraded to Sell from Neutral at B. Riley FBR
SWAV ShockWave Medical
$41.08 /

-0.7 (-1.68%)

04/21/20 Piper Sandler
ShockWave Medical price target lowered to $45 from $54 at Piper Sandler
04/06/20 Piper Sandler
ShockWave enrollment completion a 'major win,' says Piper Sandler
04/01/20 Oppenheimer
ShockWave Medical downgraded to Underperform at Oppenheimer
04/01/20 Oppenheimer
ShockWave Medical downgraded to Underperform from Perform at Oppenheimer
INFN Infinera
$5.81 /

+0.17 (+3.01%)

04/02/20 Piper Sandler
Infinera upgraded to Overweight from Neutral at Piper Sandler
03/30/20 Nomura Instinet
Infinera price target lowered to $5 from $6 at Nomura Instinet
03/27/20 Vertical Group
Infinera initiated with a Buy at Vertical Group
03/16/20 Citi
Infinera downgraded to Sell from Neutral at Citi
PBPB Potbelly
$2.98 /

-0.03 (-1.00%)

12/11/19 Piper Sandler
Potbelly downgraded to Neutral from Overweight at Piper Jaffray
VREX Varex Imaging
$25.33 /

-0.86 (-3.28%)

03/25/20 JPMorgan
JPMorgan upgrades Varex Imaging to Overweight on 'unjustified' 35% selloff
03/25/20 JPMorgan
Varex Imaging upgraded to Overweight from Neutral at JPMorgan
02/12/20 Jefferies
Jefferies downgrades Varex Imaging to Hold on limited margin visibility
02/12/20 Jefferies
Varex Imaging downgraded to Hold from Buy at Jefferies
WW WW
$23.48 /

-0.6 (-2.49%)

05/12/20 Jefferies
WW initiated with a Buy at Jefferies
05/12/20 Jefferies
WW initiated with a Buy at Jefferies
04/29/20 SunTrust
WW price target raised to $26 from $13 at SunTrust
04/29/20 B. Riley FBR
WW price target raised to $30 from $28 at B. Riley FBR
UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

03/19/20 Barclays
United Natural Foods upgraded to Equal Weight from Underweight at Barclays
03/18/20 BMO Capital
United Natural Foods upgraded to Market Perform from Underperform at BMO Capital
03/12/20 Deutsche Bank
United Natural Foods price target lowered to $7 from $10 at Deutsche Bank
01/17/20 Wells Fargo
United Natural Foods downgraded at Wells Fargo amid challenged risk/reward
ALGT Allegiant Travel
$73.36 /

-0.56 (-0.76%)

05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
Allegiant Travel price target lowered to $73 from $97 at Barclays
04/21/20 Deutsche Bank
Allegiant Travel price target lowered to $110 from $160 at Deutsche Bank
03/02/20 Evercore ISI
Allegiant Travel upgraded to Outperform from In Line at Evercore ISI
OSMT Osmotica Pharmaceuticals
$4.67 /

+0.3 (+6.86%)

03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
03/18/20 SunTrust
Osmotica Pharmaceuticals initiated with a Buy at SunTrust
03/06/20
Fly Intel: Top five analyst initiations
XP XP Inc.
$25.10 /

-0.19 (-0.75%)

04/27/20 BofA
XP Inc. downgraded to Underperform from Neutral at BofA
04/03/20 Citi
XP Inc. upgraded to Buy from Neutral at Citi
01/27/20 BTG Pactual
XP Inc. initiated with a Neutral at BTG Pactual
01/06/20 Morgan Stanley
Morgan Stanley starts XP Inc. at Overweight with $45 price target
PGNY Progyny
$20.29 /

-1.22 (-5.67%)

04/09/20 JPMorgan
Progyny should see 'very strong recovery' in 2021, says JPMorgan
11/19/19 JPMorgan
Progyny initiated with an Overweight at JPMorgan
11/19/19 Citi
Progyny initiated with a Buy at Citi
11/19/19 SVB Leerink
Progyny initiated with an Outperform at SVB Leerink
AVNW Aviat Networks
$9.45 /

-0.35 (-3.57%)

12/04/19 Northland
Aviat Networks initiated with an Outperform at Northland
XP XP Inc.
$25.10 /

-0.19 (-0.75%)

WW WW
$23.48 /

-0.6 (-2.49%)

VREX Varex Imaging
$25.33 /

-0.86 (-3.28%)

UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

UBER Uber
$32.38 /

+0.73 (+2.31%)

TCS Container Store
$2.58 /

+0.295 (+12.94%)

SWAV ShockWave Medical
$41.08 /

-0.7 (-1.68%)

PRPL Purple Innovation
$13.65 /

+0.62 (+4.76%)

PODD Insulet
$220.81 /

-3.98 (-1.77%)

PGNY Progyny
$20.29 /

-1.22 (-5.67%)

PBPB Potbelly
$2.98 /

-0.03 (-1.00%)

OSMT Osmotica Pharmaceuticals
$4.67 /

+0.3 (+6.86%)

INFN Infinera
$5.81 /

+0.17 (+3.01%)

GRUB GrubHub
$60.39 /

+13.57 (+28.98%)

EGHT 8x8, Inc.
$20.51 /

+0.63 (+3.17%)

CRHM CRH Medical
$1.89 /

-0.07 (-3.57%)

AVNW Aviat Networks
$9.45 /

-0.35 (-3.57%)

ATOM Atomera
$6.60 /

+1.09 (+19.78%)

ALGT Allegiant Travel
$73.36 /

-0.56 (-0.76%)

ADPT Adaptive Biotechnologies
$38.10 /

-0.03 (-0.08%)

ACER Acer Therapeutics
$3.75 /

+0.59 (+18.67%)

  • 15
    May
  • 13
    May
  • 13
    May
UBER Uber
$32.38 /

+0.73 (+2.31%)

PBPB Potbelly
$2.98 /

-0.03 (-1.00%)

EGHT 8x8, Inc.
$20.51 /

+0.63 (+3.17%)

ALGT Allegiant Travel
$73.36 /

-0.56 (-0.76%)

XP XP Inc.
$25.10 /

-0.19 (-0.75%)

WW WW
$23.48 /

-0.6 (-2.49%)

UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

UBER Uber
$32.38 /

+0.73 (+2.31%)

PGNY Progyny
$20.29 /

-1.22 (-5.67%)

OSMT Osmotica Pharmaceuticals
$4.67 /

+0.3 (+6.86%)

GRUB GrubHub
$60.39 /

+13.57 (+28.98%)

EGHT 8x8, Inc.
$20.51 /

+0.63 (+3.17%)

ALGT Allegiant Travel
$73.36 /

-0.56 (-0.76%)

XP XP Inc.
$25.10 /

-0.19 (-0.75%)

WW WW
$23.48 /

-0.6 (-2.49%)

UNFI United Natural Foods
$15.54 /

+2.87 (+22.65%)

UBER Uber
$32.38 /

+0.73 (+2.31%)

PGNY Progyny
$20.29 /

-1.22 (-5.67%)

INFN Infinera
$5.81 /

+0.17 (+3.01%)

GRUB GrubHub
$60.39 /

+13.57 (+28.98%)

EGHT 8x8, Inc.
$20.51 /

+0.63 (+3.17%)

ALGT Allegiant Travel
$73.36 /

-0.56 (-0.76%)

Syndicate
Acer Therapeutics files to sell 1.64M shares of common stock for holders  16:11
05/12/20
05/12
16:11
05/12/20
16:11
ACER

Acer Therapeutics

$3.79 /

+0.63 (+19.94%)

 
ShowHide Related Items >><<
ACER Acer Therapeutics
$3.79 /

+0.63 (+19.94%)

ACER Acer Therapeutics
$3.79 /

+0.63 (+19.94%)

06/26/19 H.C. Wainwright
Acer Therapeutics price target lowered to $10 from $55 at H.C. Wainwright
06/25/19 Roth Capital
Acer Therapeutics price target lowered to $9 from $66 at Roth Capital
06/25/19 Raymond James
Raymond James doesn't see path forward for Edsivo, cuts Acer to Market Perform
06/25/19 Raymond James
Acer Therapeutics downgraded to Market Perform from Outperform at Raymond James
ACER Acer Therapeutics
$3.79 /

+0.63 (+19.94%)

Hot Stocks
Acer Therapeutics enters research pact with NCATS for emetine hydrochloride » 17:41
05/11/20
05/11
17:41
05/11/20
17:41
ACER

Acer Therapeutics

$3.16 /

+0.39 (+14.08%)

Acer Therapeutics…

Acer Therapeutics announced it has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences, or NCATS, one of the National Institutes of Health, or NIH, to develop emetine hydrochloride as a potential treatment for patients with COVID-19, the disease caused by infection with the SARS-CoV-2 virus. Under the terms of the agreement, Acer and NCATS will collaborate to accelerate the clinical development of emetine, a broad-acting and potent antiviral according to various preclinical and clinical studies. Acer is in ongoing discussion with the Division of Antivirals, or DAV, at the FDA after receiving its initial written responses to the company's pre-IND package. Acer is working toward an IND submission in mid-2020 and targeting clinical trial initiation in Q3, subject to additional capital. The company has proposed an adaptive design Phase 2/3 randomized, blinded, placebo-controlled multi-center trial to evaluate the safety and antiviral activity of emetine in high-risk, symptomatic adult patients with confirmed COVID-19 infection not requiring hospitalization. The trial objectives as planned are to determine the safety and efficacy of emetine via clinical status at a specific timepoint in addition to disease resolution. Acer is concurrently pursuing several financing options, including federally-funded research and grants, to support emetine development. For example, the Biomedical Advanced Research and Development Authority, or BARDA, invited the company to present the emetine development program at the BARDA CoronaWatch meeting on May 7. BARDA CoronaWatch is a funding program providing government support for selected coronavirus projects. While Acer plans to advance emetine through IND submission, initiation of the clinical trial of emetine is contingent on the timely availability of additional capital to fund this program. Emetine will be delivered as a sterile subcutaneous injection. Acer will oversee the contract synthesis and manufacturing of emetine for clinical development and potential commercialization.

ShowHide Related Items >><<
ACER Acer Therapeutics
$3.16 /

+0.39 (+14.08%)

06/26/19 H.C. Wainwright
Acer Therapeutics price target lowered to $10 from $55 at H.C. Wainwright
06/25/19 Roth Capital
Acer Therapeutics price target lowered to $9 from $66 at Roth Capital
06/25/19 Raymond James
Raymond James doesn't see path forward for Edsivo, cuts Acer to Market Perform
06/25/19 Raymond James
Acer Therapeutics downgraded to Market Perform from Outperform at Raymond James
Hot Stocks
Acer Therapeutics in $15M stock purchase pact with Lincoln Park » 16:58
04/30/20
04/30
16:58
04/30/20
16:58
ACER

Acer Therapeutics

$2.39 /

-0.12 (-4.78%)

Acer Therapeutics…

Acer Therapeutics announced it has entered into a common stock purchase agreement for up to $15 million with Lincoln Park Capital Fund, a Chicago-based institutional investor. Under the terms of the purchase agreement and following the filing and effectiveness of a registration statement, Acer will have the right at its sole discretion, but not the obligation, to sell to LPC up to $15 million worth of shares over the 36-month term of the agreement, subject to various limitations including those under the Nasdaq listing rules. There are no upper limits to the price per share LPC may pay to purchase the shares, and the purchase price of the shares will be based on the then prevailing market prices at the time of each sale to LPC. Acer controls the timing and amount of any future sales of its stock to LPC. There are no warrants, derivatives, financial or business covenants associated with the agreements, and LPC has agreed not to cause or engage in any direct or indirect short selling or hedging of Acer's common stock. Acer may terminate the purchase agreement at any time, at its discretion, without any cost or penalty.

ShowHide Related Items >><<
ACER Acer Therapeutics
$2.39 /

-0.12 (-4.78%)

06/26/19 H.C. Wainwright
Acer Therapeutics price target lowered to $10 from $55 at H.C. Wainwright
06/25/19 Roth Capital
Acer Therapeutics price target lowered to $9 from $66 at Roth Capital
06/25/19 Raymond James
Raymond James doesn't see path forward for Edsivo, cuts Acer to Market Perform
06/25/19 Raymond James
Acer Therapeutics downgraded to Market Perform from Outperform at Raymond James

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.